IOL Chemicals and Pharmaceuticals Limited

rs,

Complex, Bandra (E) Mumbai - 400 051 Security Symbol: IOLCP BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400 001 Security Code: 524164 Subject: Investor Presentation-Q3 FY2025. D

30%

ew site Customer base across 80 countries 2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share Zero Discharge Effluent Treatment Plant Over 20 products are commercialized with 8

₹ 527

ward integrated with ~30% Global share 4 Q3 & 9M FY25 Performance Q3FY25 Financial Performance ₹ 527 Cr Total Income ₹ 51 Cr EBITDA 9.7% EBITDA Margin ₹ 21 Cr Profit After Tax 3.9% PAT Margin •

₹ 51

0% Global share 4 Q3 & 9M FY25 Performance Q3FY25 Financial Performance ₹ 527 Cr Total Income ₹ 51 Cr EBITDA 9.7% EBITDA Margin ₹ 21 Cr Profit After Tax 3.9% PAT Margin • CARE Ratings reaffirme

9.7%

4 Q3 & 9M FY25 Performance Q3FY25 Financial Performance ₹ 527 Cr Total Income ₹ 51 Cr EBITDA 9.7% EBITDA Margin ₹ 21 Cr Profit After Tax 3.9% PAT Margin • CARE Ratings reaffirmed the credit r

₹ 21

formance Q3FY25 Financial Performance ₹ 527 Cr Total Income ₹ 51 Cr EBITDA 9.7% EBITDA Margin ₹ 21 Cr Profit After Tax 3.9% PAT Margin • CARE Ratings reaffirmed the credit rating for enhanced b

3.9%

Performance ₹ 527 Cr Total Income ₹ 51 Cr EBITDA 9.7% EBITDA Margin ₹ 21 Cr Profit After Tax 3.9% PAT Margin • CARE Ratings reaffirmed the credit rating for enhanced banking facilities • Marg

Rs. 4

ntraction due to stagnant demand and pricing pressure • The Board declared an Interim Dividend of Rs. 4/- per equity share of face value of Rs 10 each. • • Post approval from Shareholders, Record Dat

Rs 10

ng pressure • The Board declared an Interim Dividend of Rs. 4/- per equity share of face value of Rs 10 each. • • Post approval from Shareholders, Record Date has been fixed for Mar 11, 2025 ’ for sub-

Rs 2

ord Date has been fixed for Mar 11, 2025 ’ for sub-division/split of face value of equity shares to Rs 2 from Rs 10 earlier. Indian Chemical Council awarded Responsible Care® logo to the Company for three

rs 9

Rs 10 earlier. Indian Chemical Council awarded Responsible Care® logo to the Company for three years 9M-FY25 Financial Performance ₹ 1569 Cr Total Income ₹ 157 Cr EBITDA 10.0% EBITDA Margin ₹ 69 Cr

₹ 1569

uncil awarded Responsible Care® logo to the Company for three years 9M-FY25 Financial Performance ₹ 1569 Cr Total Income ₹ 157 Cr EBITDA 10.0% EBITDA Margin ₹ 69 Cr Profit After Tax 4.4% PAT Margin

Regulatory Filings

4

Company

1

Investor Relations Advisors

1

Regulatory Filings

US/EU/ANVISA (Antidiabetic and potential antineoplastic used for patients with type 2 diabetes) Dedicated manufacturing block with an installed capacity of 7,200 MT/Annum

Regulatory Filings

US/EU/ANVISA Regulatory Filings: CEP approved; US DMF filed (Antiplatelet drug, used in cardiovascular therapies, preventing future heart attacks, strokes, and other clot-related diseases) Paracetamol Lamotrigine Clopidogrel Bisulphate Metformin Hydrochloride Pantoprazole Sodium Dedicated manufacturing facility with installed capacity of 240 MT/Annum, with a fully backward integrated process.

Regulatory Filings

US/EU/ANVISA/China ( Treatment for gastroesophageal reflux disease and promote healing of tissue damage caused by gastric acid) Fully backward integration process, commercialized with an installed capacity >200 MT/Annum

Company

IOL Chemicals and Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, CFO pardeepkhanna@iolcp.com www.iolcp.com

Investor Relations Advisors

Adfactors PR Pvt. Ltd. Darshan Mankad darshan.mankad@adfactorspr.com Hanishi Shah hanishi.shah@adfactorspr.com www.adfactorspr.com